Enterprise Value
87.64M
Cash
55.14M
Avg Qtr Burn
-3.097M
Short % of Float
24.31%
Insider Ownership
39.84%
Institutional Own.
31.10%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YCANTH (VP-102) Details Infectious disease, Molluscum contagiosum | Approved Quarterly sales | |
VP-102 (GMP-controlled formulation of cantharidin) Details Human papillomavirus, Genital Warts
| Phase 3 Initiation | |
VP-102 (GMP-controlled formulation of cantharidin) Details Human papillomavirus, Common Warts
| Phase 3 Initiation | |
VP-315 Details Basal cell carcinoma | Phase 2 Data readout |